Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Core Insights - Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment in areas of high unmet medical need [1][2] - The company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 1:30 p.m. ET, with a live webcast available on its website [1] - Mersana has developed proprietary ADC platforms, including Dolasynthen and Immunosynthen, which are generating a pipeline of product candidates targeting various cancers [2] Company Overview - Mersana Therapeutics specializes in novel ADCs and aims to provide new treatment options for patients [2] - The company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of HER2 [2] - Mersana regularly updates investors with relevant information on its website [2]